Genome editing: US could apply UK's approach to evaluate safety, ethics

February 25, 2016 by David Orenstein
Rapidly advancing technologies allow for editing genetic material in embryos. But will the U.S. allow that? Credit: National Human Genome Research Institute

This winter has provided several dramatic developments in the ongoing debate about whether altering the "germline" - that is, the genome of a new embryo - should be allowed. Employing the technique could permanently alter not just an individual, but also that person's future genetic lineage. In a new research essay in the journal Cell, a duo of medical and legal experts from Brown and Harvard Universities argues that if the U.S. decides to consider the practice, it has a well-drawn regulatory roadmap to follow, courtesy of the United Kingdom.

A year ago, the UK approved a medical treatment called mitochondrial replacement (MR) therapy. The mitochondria are parts within each cell that have their own small genome - distinct from that in the nucleus. Sometimes errant mitochondrial genes can cause serious health diseases. MR therapy proposes to take an egg cell from a woman donor with healthy and to swap in the nucleus of an affected mother-to-be. Once fertilized in the lab with the father's sperm, the resulting embryo would have the donor's healthful mitochondria, and the needed mix of mom and dad's nuclear DNA.

In the Cell essay, Dr. Eli Adashi, former dean of medicine and biological sciences at Brown and Glenn Cohen, professor of law at Harvard, argue that - in which scientists would alter the nuclear genome of an embryo - and MR therapy are similar enough that the principles the UK used to consider and approve MR therapy give the U.S. a ready-made framework for evaluating germline editing.

"Both must contend with breaching the germline barrier," Adashi and Cohen wrote. "Both entail the manipulation of a human embryo. Both must address significant safety concerns. Both must engage a skeptical public. Both must face up to the first-in-human imponderable. Both must grapple with ethical concerns. Both must stamp out unease with technology running unchecked. And both must assuage fears of an altered natural order known to man for millennia."

"It follows that key insights derived from the MR experience may well prove applicable and potentially helpful to deliberating the challenge."

Contradictory context

The essay appears amid rapid-fire bouts of news, some supportive and some discouraging, from the debates swirling around MR therapy and germline editing.

Earlier this month, the U.S. National Academies issued a report advising the U.S. government to follow the UK's lead - for the most part - on MR therapy. A key difference, though, was approving only the transfer of male embryos, because men don't pass on mitochondrial DNA to their offspring.

A few days before that, the UK approved editing the genomes of - those produced but not used for in vitro fertilization - for research purposes. In this case, however, the experimental embryos would be destroyed at the conclusion of the study, again preventing genetic changes from appearing in an individual or being handed down through generations.

If the U.S. government is going to consider therapeutic MR or germline editing like the U.K., Adashi said, it won't actually be able to approve any of the needed preclinical research, because of provisions tucked into to a spending law passed in December 2015. The act prohibits the Food and Drug Administration from using any appropriated monies to accept or approve any project "in which a human embryo is intentionally created or modified to include a heritable genetic modification."

That law passed within two weeks of a major summit on genome editing that brought numerous prominent scientists together in Washington DC to debate the future of the technology.

What the UK did right

In Cell, Adashi and Cohen praise how the UK grappled with five prevailing concerns during the decade-long process that led to approving MR therapy: "the presence of a compelling medical rationale, the safety and efficacy of the preclinical science, the rigor of the ethical framework, the scope of the public engagement, and the soundness of the regulatory constructs."

These same principles could guide assessments of germline editing, they wrote.

The UK, through specially convened expert panels and studies; parliamentary debate; and public forums, meetings and interviews invested heavily in examining MR therapy's ethics, safety and public concerns, they wrote.

"Applying the principles relied upon on in the regulatory evaluation of MR will go a long way towards assuring that the prospect of therapeutic genome editing in the human is the subject of a thorough, inclusive, ethical, safety-minded and confidence-inspiring process," Adashi and Cohen wrote.

Explore further: Guidelines for human genome editing

More information: Going Germline: Mitochondrial Replacement as a Guide to Genome Editing, dx.doi.org/10.1016/j.cell.2016.02.018, www.cell.com/cell/fulltext/S00 … -8674%2816%2930120-9

Related Stories

Guidelines for human genome editing

January 21, 2016
Human genome editing for both research and therapy is progressing, raising ethical questions among scientists around the world.

Is UK evaluation of reproductive tech a model for US?

April 10, 2015
When the United Kingdom resoundingly approved mitochondrial replacement therapy in February, it became the first country to give people this new medical option. In parallel it gave the United States serious cause to reflect ...

New gene editing tools force renewed debate over therapeutic germline alteration

May 1, 2015
Recent evidence demonstrating the feasibility of using novel CRISPR/Cas9 gene editing technology to make targeted changes in the DNA of human embryos is forcing researchers, clinicians, and ethicists to revisit the highly ...

Why treat gene editing differently in two types of human cells?

December 7, 2015
At the conclusion of the recent International Summit on Human Gene Editing in Washington, DC, its organizing committee released a much-anticipated statement recommending how human genetic engineering should be regulated. ...

Gene editing in embryos is fraught with scientific and ethical issues

December 2, 2015
Recent technological advances have revolutionised our ability to manipulate the genetic code, allowing us to specifically edit individual genes. Gene editing offers exciting potential for disease therapies but application ...

Recommended for you

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

Newly discovered gene variants link innate immunity and Alzheimer's disease

July 17, 2017
Three new gene variants, found in a genome wide association study of Alzheimer's disease (AD), point to the brain's immune cells in the onset of the disorder. These genes encode three proteins that are found in microglia, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.